NFKB1 and breast carcinoma: Papi et al recently demonstrated the effect of ATRA and the RXR-specific ligand 6-OH-11-O-hydroxyphenanthrene in reducing CSC phenotype of breast cancer cells by targeting NF-κB pathway56.